论文部分内容阅读
目的为明确Survivin作为膀胱肿瘤患者的肿瘤诊断和监测标志物的可能性,我们检测了Survivin在膀胱肿瘤和非肿瘤患者病变组织的Survivin蛋白及其mRNA表达情况。方法从我科住院病人和膀胱镜检患者中获取31例膀胱癌患者(实验组)和24例非肿瘤患者(对照组)的组织标本,用免疫组织化学法(IHC)和RT-PCR检测Survivin蛋白和基因在肿瘤组织和非肿瘤组织中的表达情况。并对结果行相应的统计学分析。结果IHC检测实验组和对照组Survivin蛋白的阳性率分别为74%(23/31)和4%(1/24),χ2检验P<0.001,IHC的阳性率与肿瘤的分级分期有一定的关系;实验组和对照组RT-PCR检测Survivin mRNA的表达阳性率分别为90%(30/31)和4%(1/24),χ2检验P<0.001。结论膀胱肿瘤组织Survivin蛋白和基因的表达量高于对照组,因此,Survivin有望成为膀胱瘤高危人群筛选,肿瘤诊断和监测的工具之一。
Objectives To determine the possibility of Survivin as a tumor diagnostic and monitoring marker for bladder cancer patients, we examined Survivin protein and its mRNA expression in diseased tissues of bladder and non-tumor patients. Methods Tissue specimens from 31 patients with bladder cancer (experimental group) and 24 non-tumor patients (control group) were obtained from our hospitalized patients and cystoscopy patients. Survivin expression was detected by IHC and RT-PCR Protein and gene expression in tumor tissue and non-tumor tissue. And the results of the corresponding line of statistical analysis. Results The positive rates of Survivin protein in IHC group were 74% (23/31) and 4% (1/24) in the experimental group and control group, respectively. The positive rates of IHC were correlated with the tumor staging The positive rates of Survivin mRNA in the experimental group and the control group were 90% (30/31) and 4% (1/24) respectively by RT-PCR, and the difference was significant (P <0.001). Conclusions The expression of Survivin protein and gene in bladder tumor is higher than that in control group. Therefore, Survivin is expected to be one of the tools for screening, diagnosing and monitoring tumor in high risk population of bladder cancer.